Loricrin Polyclonal Antibody, Purified

Product Details

Product Information

Intended Use:

In Vitro Diagnostic (IVD). Use in immunohistochemistry (IHC) test methods only.

The polyclonal antibody Poly19051 is used for the in vitro examination of human biological samples using immunohistochemistry (IHC) methods for the qualitative identification of Loricrin. The clinical interpretation of any staining or its absence should be complemented by morphological studies and proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

Reactivity

Human, Mouse

Immunogen

This monospecific polyclonal antibody was raised against a peptide sequence derived from the C-terminus of the mouse loricrin protein. It was subsequently purified using peptide affinity chromatography.

Formulation

Phosphate-buffered solution+ 0.03% Thimerosal.

Preparation

The antibody was purified by affinity chromatography.

Concentration

1.0 mg/ml

Storage & Handling

When stored at ≤ -20°C, product is stable until the date shown on the label. Avoid repeated freeze-thaw cycles to prevent denaturing the antibody. If thawed and stored at 2-8°C, product is stable for 24 months from the date of thaw or until the expiry date on the label, whichever comes first.

Recommended Usage

Each lot of this antibody is quality control tested by immunohistochemical staining.

The optimal working dilution should be determined for each specific assay condition.
• IHC: 1:1,000 with either biotin based detection systems such as USA Ultra Streptavidin Detection (Cat. No. 929501).

Tissue Sections: Paraffin-embedded tissues
Pretreatment: For optimal staining, the sections should be pretreated with an antigen unmasking solution such as Citrate Buffer Retrieval solution (Cat. No. 928502, 928602).
Incubation: 60 minutes at room temperature

Precautions for Use: Use appropriate personal protective equipment and safety practices per universal precautions when working with this reagent. Refer to the reagent safety data sheet.

Application References

1. Wallace L, Roberts-Thompson L, and Reichelt J. Deletion of K1/K10 does not impair epidermal stratification but affects desmosomal structure and nuclear integrity. J. Cell Sci., 125: 1750-1758, Apr 2012. PubMed
2. Bayo P, Sanchis A, Bravo A, Cascallana JL, Buder K, Tuckermann J, Schütz G, and PTrez P. Glucocorticoid Receptor Is Required for Skin Barrier Competence. Endocrinology, 149: 1377-1388, Mar 2008. [IHC] PubMed
3. Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410:710-714, 2001.
4. Yuspa SH, Kilkenny AD, Steinert PM, Roop DR. Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations in-vitro. J Cell Biol 109:1207-1217, 1989.
5. Roop DR, Cheng CK, Titterington L, Meyers CA, Stanley JR, Steinert PM, Yuspa SH. Synthetic peptides corresponding to keratin subunits elicit highly specific antibodies. J Biol Chem 259:8037-8040, 1984. 6. Suzuki K, et al. 2009. Development. 136:367. (IHC) PubMed
6. Croyle MJ, et al. Role of epidermal primary cilia in the homeostasis of skin and hair follicles. Development, 138: 1675-1685, May 2011. [IHC, IF] PubMed
7. Sengupta A, et al. 2010. PLoS One. 5:12249. (IHC) PubMed
8. Suzuki K, et al. 2009. Development. 136:367. (IHC) PubMed
9. Liakath-Ali K, et al. 2014. Nat Commun. 11:3540. (IHC) PubMed
10.  

Product Citations

1. Wallace L, et al. 2012. J Cell Sci. 125:1750-1758. PubMed
2. Suzuki K, et al. 2009. Development. 136:367-372. PubMed
3. Bayo P, et al. 2008. Endocrinology. 149:1377-1388. PubMed
4. Liakath-Ali K, et al. 2014. Nat Commun. 5:3540. PubMed
5. Croyle M, et al. 2011. Development. 138:1675-1685. PubMed
6. Sengupta A, et al. 2010. PLoS One. 5:e12249. PubMed
7. Wu N, et al. 2016. J Invest Dermatol. 136:192-201. PubMed
8. Dahlhoff M, et al. 2016. Development. 143: 1823 - 1831. PubMed
9. Matsui M, et al. 2016. J Pharmacol Sci. S1347-8613(16)30102-5. PubMed
10. Naeem A, et al. 2016. J Allergy Clin Immunol. S0091-6749(16)31377-X. PubMed
11. Shatirishvili M, et al. 2016. Cell Death Dis. 7:e2461. PubMed
12. Carceller E, et al. 2016. Sci Rep. 6:38825. PubMed
13. Madon-Simon M, et al. 2017. PLoS One. 12(6):e0180035. PubMed
14. Kousa YA, et al. 2017. Dev Dyn. 246:670. PubMed
15. Suzuki S, et al. 2019. Life Sci Alliance. 2:. PubMed
16. Lecland N, et al. 2019. Life Sci Alliance. 2:2. PubMed
17. Devos M, et al. 2017. J Invest Dermatol. 137:494. PubMed
18. Tripurani SK, et al. 2018. Mol Biol Cell. 29:2784. PubMed
19. Miao Q, et al. 2019. Nat Commun. 10:4042. PubMed
20. Niehues H, et al. 2019. J Allergy Clin Immunol. 143:1626. PubMed
21. Qu J, et al. 2018. Cell Rep. 25:3490. PubMed
22. Laurin M, et al. 2019. Elife. 8. PubMed
23. Zhang Y et al. 2018. Cell stem cell. 23(4):516-529 . PubMed
24. Han Y et al. 2019. Cell reports. 27(3):835-846 . PubMed
25. Boink MA, et al. 2018. J Tissue Eng Regen Med. 12:e1088. PubMed

RRID

AB_2565046 (BioLegend Cat. No. 905101)

Documentation

• Instructions for Use (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related FAQs

Certificate of Analysis